Cumberland Pharmaceuticals (CPIX)
Develops ifetroban for rare-disease complications while retaining a life-sciences venture interest.
$6.25
Pre-market−0.28 (−4.29%)
At close$6.53(−0.46%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 9 | 8 | 10 | 9 | 10 | 12 | 11 | 8 | 14 | 9 | 0 |
| Cost of revenue | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 0 |
| Gross profit | 8 | 8 | 7 | 8 | 8 | 8 | 10 | 9 | 7 | 11 | 7 | 0 |
| 10 | 14 | 9 | 9 | 9 | 10 | 9 | 10 | 9 | 13 | 10 | 3 | |
| Research & development | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| 7 | 8 | 7 | 7 | 7 | 8 | 7 | 7 | 7 | 10 | 8 | 3 | |
| Selling & marketing | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 5 | 0 |
| General & administrative | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 4 | 3 | 3 |
| Other expenses | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Operating income | −2 | −6 | −2 | −1 | −2 | −2 | 1 | −1 | −2 | −1 | −3 | −3 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | −6 | −2 | −1 | −2 | −2 | 1 | −1 | −2 | −1 | −3 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | −6 | −2 | −1 | −2 | −2 | 1 | −1 | −2 | −1 | −3 | −3 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −1 | −6 | −2 | −1 | −2 | −2 | 1 | −1 | −2 | −1 | −3 | −4 |
| EPS, basic | −$0.07 | −$0.44 | −$0.14 | −$0.08 | −$0.11 | −$0.14 | $0.08 | −$0.05 | −$0.13 | −$0.09 | −$0.22 | −$0.27 |
| EPS, diluted | −$0.07 | −$0.44 | −$0.14 | −$0.08 | −$0.11 | −$0.14 | $0.08 | −$0.05 | −$0.13 | −$0.09 | −$0.22 | −$0.27 |
| Weighted average shares, basic | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 15 | 15 | 15 | 15 | 15 |
| Weighted average shares, diluted | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 15 | 15 | 15 | 15 | 15 |
| EBITDA | 1 | −4 | 0 | 0 | 0 | 0 | 3 | 1 | −1 | 0 | −2 | −3 |
| Depreciation & amortization | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| EBIT | −1 | −6 | −2 | −1 | −1 | −2 | 1 | −1 | −2 | −1 | −3 | −3 |